Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood‑based parameters and ratio-Reference-Cited by-同舟云学术

Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood‑based parameters and ratio

Published:2024-01-03 Issue:2 Volume:20 Page:
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:
Short-container-title:Mol Clin Oncol

Author:

Shimada Hiroko¹,Fujimoto Akihiro¹,Matsuura Kazuo¹,Kohyama Shunsuke²,Nukui Asami¹,Ichinose Yuki¹,Asano Aya³,Ohara Masahiro¹,Ishiguro Hiroshi¹,Osaki Akihiko¹,Saeki Toshiaki¹

Affiliation:

1. Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan

2. Department of Pharmacy, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan

3. Department of Breast Oncology, Saitama Medical University Hospital, Moroyama‑machi, Saitama 350‑0495, Japan

Publisher

Spandidos Publications

Reference42 articles.

1. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B;Towle;Cancer Res,2001

2. Eribulin mesylate;Jain;Clin Cancer Res,2011

3. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study;Cortes;Lancet,2011

4. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane;Kaufman;J Clin Oncol,2015

5. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and meta-analysis;Yodying;Ann Surg Oncol,2016